A Clinical Trial to Evaluate the Effects of Super Lungs Liquid Drops on Respiratory Comfort, Airway Soothing, and Overall Well-Being

NCT07694284 | Active Not Recruiting

• 1 other identifier: SUPER-81411
• Study Type: interventional
• Target: 35
• Locations: 1 country
• Sites: 1

Brief Summary

This is a single-group, open-label, fully decentralized (virtual) clinical trial evaluating the effects of Super Lungs Liquid Drops on respiratory comfort, airway soothing, and overall well-being in generally healthy adults aged 18-65 who experience bothersome respiratory symptoms. All 35 enrolled participants will receive the active study product and self-administer 2 mL of the drops daily (two full droppers of 1 mL each, once daily with the first meal of the day) for 12 weeks.

Conditions

Coughing; Throat Irritation

Keywords

Airway Soothing; Respiratory Comfort

Outcome Measures

Primary Outcomes (2)

• Respiratory comfort

  Change in self-reported respiratory comfort assessed by questionnaires.

  Baseline, Week 2, Week 4, Week 8, and Week 12

• Normal airway function

  Change in self-reported normal airway function assessed by questionnaires.

  Baseline, Week 2, Week 4, Week 8, and Week 12

Study Arms (1)

Super Lungs Liquid Drops

EXPERIMENTAL

Dietary Supplement: Super Lungs Liquid Drops

Interventions

Super Lungs Liquid Drops DIETARY_SUPPLEMENT

All 35 participants receive Super Lungs Liquid Drops at 2 mL daily (two full droppers of 1 mL each), administered once daily with the first meal of the day, for 12 weeks.

Super Lungs Liquid Drops

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Adults aged 18-65 years.
• Over the past two months, has experienced bothersome coughing on a weekly basis.
• Anyone who has experienced issues with at least two of the following over the past four weeks: chest tightness or congestion; persistent throat irritation or itchiness; excess mucus or phlegm buildup.
• Generally healthy, without any uncontrolled chronic disease.
• Willing to maintain their current diet, sleep pattern, and activity levels for the duration of the trial.
• Resides in the United States.
• Has access to the internet and a device (smartphone, tablet, or computer) capable of completing online questionnaires.
• Willing to follow the study protocol and complete all required assessments.

You may not qualify if:

• Anyone with a known allergy or sensitivity to any of the study product ingredients.
• Anyone with a known allergy to plants in the Asteraceae/Compositae family.
• Women who are pregnant, breastfeeding, or planning to become pregnant during the study period.
• Anyone currently taking immunosuppressant medications (e.g., cyclosporine, methotrexate, biologics such as adalimumab or infliximab).
• Anyone with a diagnosed autoimmune disorder (e.g., lupus, rheumatoid arthritis, multiple sclerosis).
• Anyone with uncontrolled hypertension or currently taking antihypertensive medications, diuretics, or corticosteroids.
• Anyone currently taking anticoagulant or antiplatelet medications (e.g., warfarin, heparin, clopidogrel).
• Anyone with a chronic health condition that could impact their participation in this study, such as cancer, mental health disorders, a history of serious illness in the last three months, a history of substance abuse, or planned surgery during the study period.
• Anyone with a history of alcohol use disorder or currently in alcohol recovery.
• Anyone currently participating in another research study or who plans to participate in another study during the study period. (

Sponsors & Collaborators

• SuperBonsai Inc.: lead
• Citruslabs: collaborator

Study Sites (1)

Citruslabs

Las Vegas, Nevada, 89118, United States

Location

MeSH Terms

Conditions

Cough

Condition Hierarchy (Ancestors)

Respiration Disorders; Respiratory Tract Diseases; Signs and Symptoms, Respiratory; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 2, 2026
• First Posted: July 9, 2026
• Study Start: July 2, 2026
• Primary Completion: August 1, 2026
• Study Completion: August 1, 2026
• Last Updated: July 9, 2026

Record last verified: 2026-07

Locations

US (1)